Gilead Sciences, Inc.

Cv Therapeutics, Inc.

The Endowment for Research in Human Biology, Inc.

Matthew Abelman

Jeff A Zablocki

Robert H Jiang

Elfatih O Elzein

Rao V Kalla

Thao Perry

Xiaofen Li

Dmitry Koltun

Tetsuya Kobayashi

Michael Organ

Wing Ming Keung

Guoxin Tao

Kwan Leung

Nancy Chu

Melanie Boze

Yaroslav Bilokin

Ivan Diamond

Lina Yao

Peidong Fan

Maria Pia Arolfo

Zhan Jiang

The present invention relates to novel heterocyclic compounds and to their use in the treatment of various disease states, including cardiovascular diseases and diabetes. In particular embodiments, the structure of the compounds is given by Formula (I): wherein Q1, Q2, R2, R3, R4, R5, and R6 are as described herein. The invention also relates to methods for the preparation of the compounds, and to pharmaceutical compositions containing such compounds.

Substituted heterocyclic compounds

The present invention relates to sodium channel inhibitors of Formula I: in which R, R, R, R, R, R, and Rare as defined above, and to their use in the treatment of various disease states, including cardiovascular diseases and diabetes.

Fused heterocyclic compounds as ion channel modulators

The present invention relates to sodium channel inhibitors of Formula (I): in which R, R, R, R, R, X, Y, and Z are as defined herein, and to their use in the treatment of various disease states, including cardiovascular diseases and diabetes. The invention also relates to methods for the preparation of the compounds, and to pharmaceutical compositions containing such compounds.

Substituted heterocyclic compounds as ion channel modulators

The present invention relates to compounds that are sodium channel inhibitors and to their use in the treatment of various disease states, including cardiovascular diseases and diabetes. In particular embodiments, the structure of the compounds is given by Formula (IA) or (IB): as further described herein. The invention also relates to methods for the preparation of the compounds, and to pharmaceutical compositions containing such compounds.

Disclosed are novel isoflavone derivatives having the structure of Formula I which are useful as ALDH-2 inhibitors for treating mammals for dependence upon drugs of addiction, for example addiction to dopamine-producing agent such as cocaine, morphine, amphetamines, nicotine, and alcohol.

ALDH-2 inhibitors in the treatment of addiction

Disclosed are novel quinazolinone derivatives of formula: wherein:

Quinazolinone derivatives as ALDH-2 inhibitors

The present invention provides compounds useful for increasing cellular ATP binding cassette transporter ABCA1 production in mammals, and to methods of using such compounds in the treatment of coronary artery diseases, dyslipidiemias and metabolic syndrome. The invention also relates to methods for the preparation of such compounds, and to pharmaceutical compositions containing them.

ABCA1 elevating compounds

Growing community of inventors

Mountain View, CA, United States of America

Matthew Abelman